This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Atrophy or Vaginal Diseases
and you are
between 40 and 80
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The objective of the study was to assess the long-term safety of daily doses of ospemifene 60 mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a uterus.

Provided treatments

  • Drug: Ospemifene 60Mg Oral Tablet

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01586364. The sponsor of the trial is Shionogi and it is looking for 301 volunteers for the current phase.
Official trial title:
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310